Pharmafile Logo

PHARMA POST COVID-19: REVOLUTION OR EVOLUTION?

- PMLiVE

Post-COVID-19 thinking: outputs from a thought leader forum

On 14 May 2020, a group of industry experts across pharma and biotech Zoomed together to share reflections on the impact of COVID-19 so far and the implications for how we should evolve in the coming months and years:
Download full article here

EXECUTIVE SUMMARY

Biggest impact of COVID-19

  • COVID-19 has had a significant impact on how the industry works; maintaining individuals’ well-being and finding the best ways to integrate digital has challenged many companies
  • Clinical trials have been affected, in particular, recruitment and progress. It was also noted that certain metrics and data collection are likely to be affected and may have an impact on future regulatory submissions
  • Our forum concluded that in general we expect sales of established medicines to be above expectations, with newer therapies likely to be behind budget, due mainly to patients not attending clinic and a reduced new/switched/repeat dynamic

Biggest concerns

  • We highlighted concern that future pricing may be affected. Government debt has been affected by COVID-19 and this may impact future pricing negotiations and also see a quicker transition to outcomes-based pricing
  • Our recommendation is that the industry needs to continue to build trust. Vaccine and COVID-19 treatment costs will be high-profile negotiations and may affect reputation or profits.
  • There is an opportunity for the industry to transition its reputation from medicines developers to healthcare providers
  • The industry needs to evolve how it works digitally, but we don’t expect a revolution, rather a gradual upskilling of organisations and of its people to enable more effective working. How this is done, however, is still uncertain, and is an opportunity for better collaboration

Biggest opportunities

  • We concluded that re-shaping how the field force evolve and work is a huge opportunity for the industry to add more value to society. How to add value through a truly multi-channel approach is an exciting opportunity for our industry, and a key opportunity for future discussion
  • The industry has spent millions on congress attendance for so many years. How the industry has recently operated offers an opportunity to re-think how to engage with congresses, but more importantly how to engage with healthcare professionals throughout the year. We don’t see a time when congresses are not important, but whether medical communications are anchored to congresses in the future is an opportunity to explore
  • It’s difficult to predict the new normal, but we know digital and user experience will be critical to effective commercialisation. This provides an exciting opportunity for our industry to create compelling digital experiences for brand and organisations to communicate with their audiences
  • We expect increased pricing pressure in the future. The organisations that adapt best, by providing real-world evidence, outcomes-based evidence and pricing, and support service re-design, will lead the future industry

Download full article here

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

The winning programme - Treating beyond symptoms in IBD: The Steroid Assessment Tool. Our approach to medical education is really helping to improve patient outcomes and change lives.

Lucid Group shines at the Communiqué Awards

Lucid Group’s commitment to be a leader in medical education was recognised at the Communiqué Awards 2016 in London last night, where the agency received three awards, including being highly...

Developing Medical Education That Advances Patient Outcomes

As pressure mounts on the pharmaceutical industry to demonstrate a tangible and positive impact on patients’ lives, understanding barriers to specific clinician behaviours is key to achieving measurable change in...

Future-proofing with a comprehensive talent development strategy

Lucid Group is an award-winning group of specialist medical education companies. Over the years, Lucid has developed a strong culture of empowerment, thought-leadership, entrepreneurship and passion to improve outcomes for...

Lucid reach the shortlist for Communiqué 2016 in SIX categories

Lucid Group are celebrating the news that for the first time they have been shortlisted in six different categories at this year’s Communiqué awards.  The categories are:Excellence in Communications of...

Lucid Co-founder and COO discusses the changing landscape of healthcare communications

In May’s issue, Jan Steele (Lucid co-founder and COO) talks to PME about the importance of demonstrating value with medical education via validated improvements in patient outcomes. Jan explains that...

New talent blooms at Lucid Group

Spring has most definitely sprung at Lucid Group as they welcome three new employees to their team. Laura Cunliffe joins as a Senior Account Manager at Leading Edge and will...

The art of changing behaviour with virtual technology

In April’s issue of PME, Ella Nuttall (Health Psychology Specialist at Lucid Group) explains how changing behaviour requires a combination of science and art. She outlines how the impact of...

Lucid CEO discusses the importance of company culture

In April’s Smart Thinking blog on pmlive.com, Dennis O’Brien (Lucid CEO) discusses company culture and how individual contribution is everything.Dennis explains that, despite organisations being obsessed with meeting financial targets every...

There's never a dull moment at Lucid Group

Andrea Hamlin, Angela Tye-Galichet, Emma Herring and Ify Onyeaso were all treated to a fabulous lunch with the Lucid Co-Founders, Dennis O’Brien and Jan Steele in celebration of their 5...